|
|
|
|
|
| |
Current
Issues - Newsletter
September 2006 |
|
|
|
|
| |
New US Patent granted to Sabinsa
|
|
| |
| |
|
Sabinsa has been granted US patent
#7,063,861, for Garcitrin®, a
branded ingredient that offers
effective weight management support.
The patent, entitled "Bio-available
Composition of Natural and Synthetic
HCA" describes the use of the natural
bioactive hydroxycitric acid (HCA) in
combination with garcinol in weight
management.
HCAis a well researched compound,
clinically proven to support weight
management. However, because HCA
is poorly absorbed into target cells,
it is ineffective alone as an inhibitor
for adenosine triphosphate citratelyase,
a key enzyme in body fat formation.
|
Sabinsa's proprietary ingredient
Garcitrin combines HCA with garcinol,
a polyisoprenylated benzophenone
isolated from Garcinia cambogia and
Garcinia indica
fruits.
The combination of
calcium salt
HCA and garcinol
reduces
fatty acid and
lipid synthesis
and improves
lean body
mass more
effectively than
HCA alone, as observed in a controlled
clinical study. Garcitrin supported a
reduction in total body weight, body
mass index, body fat and perceived
appetite level, as well as increase lean
body mass and body water content,
much more efficiently than HCA alone. |
|
|
|
|
|
|
| |
Ocufors™
Eye drop solutions for Glaucoma Treatment |
|
| |
| |
Sabinsa Corporation has been
granted permission by the Drugs
Controller General of India to manufacture
and market Ocufors™, a patented
ophthalmic solution containing one
percent forskolin, for the treatment of
glaucoma. This is the first time that the
government of India has approved a
product developed from natural sources
for use as a pharmaceutical grade drug.
“Research and development has
always been strength and focus for
Sabinsa, and through our ongoing
efforts we were able to develop this
stable, water-soluble forskolin solution
that has been shown in clinical trials
to be 30 percent more effective than
the most popular glaucoma treatment
on the world market today,” noted
Dr. Muhammed Majeed, founder and
CEO, Sabinsa Corporation. “It is an
honor to receive this approval, which
speaks highly about our stringent
safety, efficacy and quality standards,
which we apply to all of our
ingredients whether they be prescription
grade, generic commodities
or our branded offerings.”
Glaucoma is a degenerative disease
of the optic nerve, often caused by
increased pressure inside the eye.
Glaucoma affects more than 50 million
individuals worldwide and is the
second leading cause of blindness
across the globe. Ocufors, which is
administered as an eye drop, offers an
effective treatment for glaucoma with
minimal side effects. Sabinsa is currently
seeking registration for Ocufors in
the U.S., Europe and Australia.
The active ingredient in Ocufors, forskolin, is derived from the herb
Coleus forskohlii, a plant native to subtropical
and warm temperate habitats,
and a member of the mint family.
Sabinsa holds U.S. Patent #6,960,300
and pending international patent applications
for this composition. |
|
|
|
|
|
| |
Sabinsa Corporation opens New office in Malaysia
|
|
| |
| |
new office in Malaysia to cater to
the growing Southeast Asian market
for nutraceuticals and cosmeceuticals.
Sabinsa Malaysia is located in the
flourishing business city of Petaling
Jaya, near the capital city, Kuala
Lumpur.
Sujith Sathyadas is Business
Development Manager based at Sabinsa
Malaysia. He holds a Masters degree
in business administration from the
prestigious Indian Institute of Management
in Calcutta. He previously worked
with the Nicholas Piramal group in
India in their corporate strategy team.
Ms. Jamuna Imee Ramanadan, office
manager, helps Mr. Sathyadas with
the day to day office operations.
The contact information for Sabinsa
Malaysia is:
Sabinsa Malaysia Sdn Bhd
W-10-07, Amcorp Business Suite
Menara Melawangi
18 Persiaran Barat
Petaling Jaya
Selangor 46050
Malaysia
Tel: + 60-379-606-535
Fax: + 60-379-607-535
Email: sujith@sabinsa.com |
|
|
|
|
|
| |
Continued Success for
Sabinsa on Wheels Tour |
|
| |
| |
Ms Anju Majeed presenting an overview
of
Analytical Capabilities
|
Sabinsa Corporation successfully continued
its multi-city "Sabinsa on
Wheels" tour with one-day seminar
presentations in Salt Lake City, Utah
and Los Angeles, California. Sabinsa
scientists and invited speakers provided
nutraceutical and cosmeceutical industry
members with updated information
on the company's ingredient research
and development, manufacturing capabilities
and proprietary technology.
Speakers from Sabinsa's scientific
team included Dr. Muhammed Majeed,
Dr. Vladimir Badmaev, Dr. Lakshmi Prakash, Dr. Kalyanam Nagabhus
hanam and Ms. Anju Majeed. In Utah,
Madan Mohan Chaturvedi, Ph.D., visiting
professor at the M.D. Anderson
Cancer Center at the University of
Texas, presented research surrounding
the ability of curcuminoids and
boswellic acids to inhibit inflammation.
In Los Angeles, Michael Godard, Ph.D.,
highlighted findings from a clinical trialhe spearheaded surrounding Sabinsa’s
ForsLean® ingredient, and Milan Fiala,
M.D., researcher at the UCLA School of
Medicine spoke on the molecular mechanisms
of curcuminoids in supporting
immune functions and healthy aging.
|
Dr. Fiala speaks at SOW in LA
|
SOW Utah
|
Dr Chaturvedi speaks at SOW in Utah |
| |
|
| |
|
|
|
|
|
|
|
| |
Product Ads |
|
| |
| |
Look for new product advertisements
in the following publications:
|
| |
- Chemical Market Reporter
- Cosmetics & Toiletries, HAPPI
- Soap Perfumery & Cosmetics
- Natural Products Insider
- Nutritional OutLook
- Functional Foods and
- Nutraceuticals
|
|
|
|
|
|
| |
Sabinsa Shows |
|
| |
| |
IFSCC meeting
October 16 - 19, 2006
Osaka, Japan
CPhI Worldwide
October 3 - 5, 2006
Paris, France
SupplySide West
October 18 - 20, 2006
Las Vegas, NV
|
|
|
|
|
|
| |
Products |
|
| |
|
|
| |
|
|
| |
The products offered by
Sabinsa Corporation are
 |
|
| |
|
|
| |
"The information
presented in the "Current Issues" Newsletter
from Sabinsa Corporation is for informational purposes
only. It is abstracted from web and print media
sources. Readers are advised to refer to the original
sources for additional information". |
|
|
|
| |
|
|
|
